ZELTIA RAISES EUR 65 MILLION

Zeltia S.A., the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified institutional investors at a price of Eur 6.05 per share. This transaction is one of the four largest executed in European biotech in the last four years. The funds raised will be used to further the continued research, development and commercialisation of cancer products being developed by PharmaMar, Zeltia's biopharmaceutical subsidiary. HSBC acted as sole bookrunner for the transaction.

Presseportal (http://www.presseportal.de/story.htx?nr=693708)